MA-ROSLINCT
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.
Professor Sir Peter Mathieson brings an exceptional wealth of experience in higher education, medical research, and organisational leadership. Currently serving as the Principal of the University of Edinburgh since 2018, Sir Peter also holds Honorary Professorships in Medicine at the Universities of Edinburgh, Hong Kong, and Bristol. His illustrious career includes notable roles such as President of the University of Hong Kong (2014-18) and Dean of the Faculty of Medicine & Dentistry at the University of Bristol (2008-14). Sir Peter was knighted in the 2023 New Year Honours for his services to higher education, reflecting his significant contributions to the field. Additionally, Sir Peter has held numerous non-executive and trustee roles, including positions with the Renal Association, Council for the Advancement and Support of Education (CASE), Scottish Funding Council, and Newbattle Abbey College Trust. His career highlights also include tenure as an honorary consultant nephrologist with a clinical interest in autoimmune diseases and renal transplantation. He has led a significant research group in Bristol and contributed extensively to medical education and clinical research, particularly in Africa. His publication record includes 327 works, covering clinical trials, laboratory research, and societal matters, and he has been a driving force in academic careers both in the UK and internationally.
Alexander Vos is a biotech leader with 30 years of experience, specializing in biopharmaceuticals and cell & gene therapy. He started at McKinsey & Co. and held executive roles at Genzyme Therapeutics Europe. He was CEO of MediService AG, PAION AG's Deputy-CEO and COO, and led PharmaCell BV to a successful sale to Lonza. Vos also served as CEO of VarmX and VectorY, setting strategy and raising significant funds for these companies. Currently, he sits on several biotech boards and is a Venture Partner at BioGeneration Ventures. He holds an MS in Pharmacy and Pharmacology and an MBA from Stanford University. Alexander Vos's proven leadership in advancing innovative therapies and achieving successful exits for investors will be invaluable to RoslinCT. His skills in biotech strategy development, operations, and M&A will complement the existing strengths of the board.
"We are excited to welcome both Professor Sir Peter Mathieson and Alexander Vos to our Board," said Geoffrey Hamilton Fairley, Executive Chairman of the RoslinCT Group. "Sir Peter's extensive experience in academic leadership and his proven track record in advancing medical research and education, combined with Alexander's strategic insight and wealth of experience in biotech and cell and gene therapy, align perfectly with RoslinCT's mission. Their combined expertise will be instrumental as we continue to develop and manufacture cutting-edge cell and gene therapies."
"I am honoured to join RoslinCT at such an exciting time for the company and the field of cell and gene therapy," said Sir Peter Mathieson. "I look forward to contributing to RoslinCT's innovative efforts to bring life-saving therapies to patients worldwide."
Alexander Vos added, "I am excited to be part of RoslinCT's journey and to support its mission to advance cell and gene therapies. The company is at the forefront of groundbreaking science, and I am eager to contribute to its continued success."
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialisation.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625300790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global, Inc. Announces Pricing of its Initial Public Offering24.1.2025 01:04:00 CET | Press release
Venture Global, Inc. (“Venture Global”) announced today the pricing of its initial public offering of 70,000,000 shares of its Class A common stock, par value $0.01 (“Class A common stock”) at a public offering price of $25.00 per share. In connection with the offering, Venture Global has granted the underwriters a 30-day option to purchase up to an additional 10,500,000 shares of Class A common stock. The shares of Class A common stock are expected to begin trading on the New York Stock Exchange on January 24, 2025 under the symbol “VG”. The closing of the offering is expected to occur on January 27, 2025, subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC, J.P. Morgan (each listed alphabetically) and BofA Securities are acting as joint lead book-running managers. ING, RBC Capital Markets, Scotiabank, Mizuho, Santander, SMBC Nikko, MUFG, BBVA, Loop Capital Markets, Natixis, Deutsche Bank Securities, Wells Fargo Securities and Truist Securities are act
IFF to Release Fourth Quarter & Full Year 2024 Results on Feb. 18, 2025; IFF to Present at 2025 CAGNY Conference on Feb. 20, 202523.1.2025 22:24:00 CET | Press release
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2024 earnings results following the market close on Tuesday, Feb. 18, 2025. The management team will host a live webcast on Wednesday, Feb. 19, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 20, 2025 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enh
AIT Worldwide Logistics executives appointed to new leadership roles23.1.2025 20:04:00 CET | Press release
Chief Development Officer, Ray Fennelly, Chief Information Officer, Ann Nemphos, to guide company towards achieving five-year goals AIT Worldwide Logistics, a global supply chain solutions leader, has named Ray Fennelly to the position of chief development officer (CDO) and Ann Nemphos to chief information officer (CIO). This executive management reorganization improves the alignment of the company’s top leadership with its five-year growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123094755/en/ In their newly-appointed roles, Chief Development Officer, Ray Fennelly, and Chief Information Officer, Ann Nemphos, are positioned to boost support for AIT’s five-year strategic plan. (Photo: Business Wire) Fennelly, a veteran of both the company and the logistics industry, started with AIT 30 years ago and has held numerous leadership roles in that time, most recently serving as CIO. He has been intimately involve
SES Announces Completion of €100m Open Market Repurchase of its NC625 Securities23.1.2025 18:58:00 CET | Press release
SES S.A. announces it has repurchased in the open market an aggregate amount of €99,978,000 principal amount of its €625,000,000 Deeply Subordinated Fixed Rate Resettable Securities issued on 27 May 2021. In accordance with the terms and conditions of the Securities, the purchased Securities will be cancelled. Following these transactions, the outstanding principal amount of the Securities is €525,022,000. Payment in relation to the Securities will be made in accordance with the usual procedures of Clearstream, Luxembourg and/or Euroclear. The success of these transactions reduces SES's outstanding debt obligation, demonstrating SES’s financial flexibility and its strong cash-generation profile. SES may seek to make further repurchases of its Securities from time to time, subject to market conditions. This announcement does not constitute or form part of an offer to sell or purchase, or a solicitation of an offer to sell or purchase the Securities or any other securities. Follow us on:
InMotion Ventures Invests $2 Million in Cyclic Materials, Extending Series B to $55 Million23.1.2025 15:00:00 CET | Press release
The Series B funding will be used to support the opening of Cyclic Materials’ first commercial facilities in the US and Europe Cyclic Materials, the advanced recycling company building a circular supply chain for Rare Earth Elements and other critical materials, today announced a $2 million investment from InMotion Ventures, the investment arm of Jaguar Land Rover (JLR). This latest backing lifts the company’s Series B round to $55 million, underscoring its critical role in advancing sustainable supply chains for the automotive industry and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123234060/en/ Cyclic Materials extracts REEs from various end-of-life products, including EVs, consumer electronics, and medical equipment. Pictured are recycled EV and hybrid vehicle motors. (Photo: Business Wire) Rare Earth Elements (REEs) are an essential component in permanent magnets, which are found in everything from data ce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom